Recommended Alerts

Sign Up For Alerts

Developments in Drug Pricing and Price Reporting as the Congressional Recess Approaches (August 2021)

As the August congressional recess approaches, there have been several developments in the drug pricing/price reporting space. All branches of government have worked to tackle drug pricing in recent months, and by late August we may have a much stronger sense of the direction the Biden Administration intends to take to address drug pricing through administrative action.

Read More

Drug Pricing: What Happened in 2019 and What to Watch in 2020

Practices: Health Care, Life Sciences, Drug Pricing & Price Reporting

Printer-Friendly Version

Have you heard that drug prices are too high? If not, you have not been listening to President Donald Trump, Secretary of Health and Human Services (“HHS”) Alex Azar, or almost any member of Congress. In the past year, a dizzying array of drug pricing actions and proposals have come out of the White House and Congress, as well as the governor’s offices and legislative halls in most states.

Click here to read the full Alert.

Printer-Friendly Version

Cookie Settings